CD274 and cancer: Cancer immunotherapy with antibodies against PD-1 and the corresponding PD-L1 ligand has recently been shown to be effective in treating certain types of cancer, presumably by potentiating the immune response to tumor antigens (Brahmer et al., 2012; Topalian et al., 2012; Wolchok et al., 2013).